# BioFreedom QCA Study in CAD Patients

Study · id `cardio:ct-nct03307213` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03307213](<https://clinicaltrials.gov/study/NCT03307213>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03307213

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is unknown. It enrolled 200 participants.

## Technical summary

Registry record NCT03307213. Randomized; single masking; primary purpose treatment. Start 2018-06-19 (actual); primary completion 2019-09-30 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 200 participants (enrolled count; ClinicalTrials.gov record NCT03307213, source copy `cardio:ctgov-nct03307213-2019-12-24`, retrieved 2026-10-26)
- Started: 2018-06-19 (actual) (ClinicalTrials.gov record NCT03307213, source copy `cardio:ctgov-nct03307213-2019-12-24`, retrieved 2026-10-26)
- Primary completion: 2019-09-30 (actual) (ClinicalTrials.gov record NCT03307213, source copy `cardio:ctgov-nct03307213-2019-12-24`, retrieved 2026-10-26)
- Completion: 2021-03-31 (anticipated) (ClinicalTrials.gov record NCT03307213, source copy `cardio:ctgov-nct03307213-2019-12-24`, retrieved 2026-10-26)
- Countries: Denmark; Spain (ClinicalTrials.gov record NCT03307213, source copy `cardio:ctgov-nct03307213-2019-12-24`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03307213-2019-12-24`, retrieved 2026-10-26)

## The registry's words

- Brief title: BioFreedom QCA Study in CAD Patients
- Acronym: BioFreedomQCA
- Condition: Coronary Artery Disease
- Condition: Cardiac Death
- Condition: Myocardial Infarction
- Intervention (Device): BioFreedom™ CoCr Biolimus A9™ stent
- Intervention (Device): BioFreedom™ SS Biolimus A9™ stent
- Lead sponsor: Biosensors Europe SA
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry lists this organization as the lead sponsor: Biosensors Europe SA (`cardio:org-biosensors-europe-sa`)

## Provenance

Content hash: 9c8d59d57178ddc38758468a92d3dffc3b34f344ecf245ea4711a0526d97057c
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
